Japanese firm Santen Pharmaceutical and Orbis International in the US have announced a long-term, ten-year partnership to tackle the increasing burden of eye diseases in low- and middle-income countries, especially in Asia.
NEW YORK, Oct. 7, 2020 /PRNewswire/ -- Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) and Orbis International (hereinafter, Orbis) today announced a long-term, ten-year partnership to tackle the increasing burden of eye diseases in low- and middle-income countries, especially in Asia. Under this long-term partnership, Santen and Orbis will accelerate the growth of quality eye care systems by building the capacity of eye care professionals, developing digital technology and increasing awareness of the importance of eye health.
SINGAPORE and MELBOURNE, Australia, June 3, 2020 /PRNewswire/ -- A NOVEL marine-derived drug to treat Small Cell Lung Cancer (SCLC) has been granted a provisional designation by the Therapeutic Goods Administration (TGA), based on encouraging results from an international trial evaluating its safety and efficacy in several solid tumours, including SCLC.